<DOC>
	<DOCNO>NCT01668641</DOCNO>
	<brief_summary>- Ninety patient suffer active rheumatoid arthritis despite continued treatment methotrexate evaluate improvement disease activity take GLPG0634 ( 4 different dos evaluate ) match placebo 4 week . - During course study , patient also examine side effect may occur , amount GLPG0634 present blood well effect GLPG0634 disease- mechanism action-related parameter blood determine .</brief_summary>
	<brief_title>Dose-ranging Study With GLPG0634 Methotrexate-refractory Active Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have active RA show five swollen joint ( 66joint count ) , five tender joint ( 68joint count ) , serum CRP ≥1.0 mg/dL ; Have receive methotrexate 12 week longer stable dose 7.5 25 mg/week least 4 week prior screen willing continue regimen duration study ; If take oral steroid , dose ≤10 mg/day prednisone prednisone equivalent stable least 4 week prior screen ; If take nonsteroidal antiinflammatory drug ( NSAIDs ) , must stable dose least 2 week prior screen ; Female subject must negative pregnancy test unless surgically sterile postmenopausal least one year ; Women childbearing potential must use medically acceptable mean birth control agree continue use study least 12 week last dose study drug . Sexually active men must agree use medically acceptable form contraception study continue use least 3 month last dose study drug ; Able willing sign inform consent prior screen evaluation agree schedule assessment . Treatment diseasemodifying antirheumatic drug ( DMARDs ) , background methotrexate ; Current previous RA treatment biological agent , exception biologics administer clinical study set six month prior screen ( 12 month rituximab B cell deplete agent ) ; Previous treatment time cytotoxic agent , methotrexate , screen ; Previous use study drug GLPG0634 ; Receipt intraarticular parenteral corticosteroid injection within 4 week prior screen ; Known hypersensitivity study drug ingredient significant allergic reaction drug determine Investigator ; Positive serology HIV1 2 hepatitis B C , history hepatitis cause exception hepatitis A ; History inflammatory rheumatological disorder RA ; History tuberculosis ( TB ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Methotrexate insufficient responder</keyword>
</DOC>